Evidence map›Paper›PMID 39066457›Full record

ReviewVaccines2024

The Problem with Delaying Measles Elimination.

Natasha S Crowcroft, Anna A Minta, Shelly Bolotin, Tania Cernuschi, Archchun Ariyarajah, Sébastien Antoni, Mick N Mulders, Anindya S Bose, Patrick M O'Connor

Abstract readReview
In one paragraph

Review in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Progress Toward Measles Elimination - Worldwide, 2000-2023.MMWR. Morbidity and mortality weekly report · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Natasha S CrowcroftImmunization, Vaccines and Biologicals, World Health Organization, 1211 Geneva, Switzerland.ORCID 0000-0002-6761-8783
Anna A MintaImmunization, Vaccines and Biologicals, World Health Organization, 1211 Geneva, Switzerland.
Shelly BolotinDalla Lana School of Public Health, University of Toronto, Toronto, ON M5S 3H2, Canada.
Tania CernuschiImmunization, Vaccines and Biologicals, World Health Organization, 1211 Geneva, Switzerland.
Archchun AriyarajahDalla Lana School of Public Health, University of Toronto, Toronto, ON M5S 3H2, Canada.
Sébastien AntoniImmunization, Vaccines and Biologicals, World Health Organization, 1211 Geneva, Switzerland.ORCID 0000-0002-0911-0711
Mick N MuldersImmunization, Vaccines and Biologicals, World Health Organization, 1211 Geneva, Switzerland.ORCID 0000-0002-5332-2690
Anindya S BoseImmunization, Vaccines and Biologicals, World Health Organization, 1211 Geneva, Switzerland.ORCID 0000-0002-7657-8648
Patrick M O'ConnorImmunization, Vaccines and Biologicals, World Health Organization, 1211 Geneva, Switzerland.

Funding

World Health Organization 001
6 · The paper itself

Abstract

Measles is a highly infectious disease leading to high morbidity and mortality impacting people's lives and economies across the globe. The measles vaccine saves more lives than any other vaccine in the Essential Programme of Immunization and is also the most cost-effective vaccine, with an extremely high return on investment. This makes achieving measles elimination through vaccination a key child health intervention, particularly in low-income countries, where the overwhelming majority of measles deaths continue to occur. All countries and regions of the world have committed to achieving measles elimination, yet many have faced challenges securing political commitment at national and global levels and predictable, timely, and flexible support from global donors, and experienced setbacks during the COVID-19 pandemic. This has happened against a backdrop of stagnant measles vaccination coverage and declining enthusiasm for vertical programmes, culminating in a World Health Organization Strategic Advisory Group of Experts (WHO SAGE) review of the feasibility of measles eradication in 2019. Sustaining the elimination of measles long term is extremely difficult, and some countries have lost or nearly lost their measles elimination status in the face of ongoing importation of cases from neighbouring or closely connected countries in which elimination had been delayed. Thus, a widening equity gap in measles immunisation coverage creates challenges for all countries, not just those facing the greatest burden of measles morbidity and mortality. Delaying elimination of measles in some countries makes it cumulatively harder for all countries to succeed for three principal reasons: increased inequity in measles immunisation coverage makes outbreaks more likely to happen and to be larger; political will is very difficult to sustain; and immunity may wane to a point that transmission is re-established. New strategies are needed to support countries and regions in their vision for a world without measles, including ways to galvanise domestic, regional and global resources and ignite the political will that is essential to make the vision a reality.

Indexed as

eliminationMeaslesvaccination programmesvaccine equitywaning immunity

Identifiers

PMID39066457
PMCPMC11281398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.